🎉 M&A multiples are live!
Check it out!

Acumen Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Acumen Pharmaceuticals and similar public comparables like Pharming, Benevolent AI, and Vivoryon Therapeutics.

Acumen Pharmaceuticals Overview

About Acumen Pharmaceuticals

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.


Founded

1996

HQ

United States of America
Employees

61

Website

acumenpharm.com

Financials

LTM Revenue n/a

LTM EBITDA -$120M

EV

-$76.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Acumen Pharmaceuticals Financials

Acumen Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of -$120M.

In the most recent fiscal year, Acumen Pharmaceuticals achieved revenue of n/a and an EBITDA of -$98.1M.

Acumen Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Acumen Pharmaceuticals valuation multiples based on analyst estimates

Acumen Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$51.6M -$98.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$42.9M -$52.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Acumen Pharmaceuticals Stock Performance

As of April 15, 2025, Acumen Pharmaceuticals's stock price is $1.

Acumen Pharmaceuticals has current market cap of $66.6M, and EV of -$76.2M.

See Acumen Pharmaceuticals trading valuation data

Acumen Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$76.2M $66.6M XXX XXX XXX XXX $-1.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Acumen Pharmaceuticals Valuation Multiples

As of April 15, 2025, Acumen Pharmaceuticals has market cap of $66.6M and EV of -$76.2M.

Acumen Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Acumen Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Acumen Pharmaceuticals and 10K+ public comps

Acumen Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$76.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Acumen Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Acumen Pharmaceuticals Valuation Multiples

Acumen Pharmaceuticals's NTM/LTM revenue growth is n/a

Acumen Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.9M for the same period.

Over next 12 months, Acumen Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Acumen Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Acumen Pharmaceuticals and other 10K+ public comps

Acumen Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 90% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Acumen Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Acumen Pharmaceuticals M&A and Investment Activity

Acumen Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Acumen Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Acumen Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Acumen Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Acumen Pharmaceuticals

When was Acumen Pharmaceuticals founded? Acumen Pharmaceuticals was founded in 1996.
Where is Acumen Pharmaceuticals headquartered? Acumen Pharmaceuticals is headquartered in United States of America.
How many employees does Acumen Pharmaceuticals have? As of today, Acumen Pharmaceuticals has 61 employees.
Who is the CEO of Acumen Pharmaceuticals? Acumen Pharmaceuticals's CEO is Mr. Daniel O'Connell.
Is Acumen Pharmaceuticals publicy listed? Yes, Acumen Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Acumen Pharmaceuticals? Acumen Pharmaceuticals trades under ABOS ticker.
When did Acumen Pharmaceuticals go public? Acumen Pharmaceuticals went public in 2021.
Who are competitors of Acumen Pharmaceuticals? Similar companies to Acumen Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Acumen Pharmaceuticals? Acumen Pharmaceuticals's current market cap is $66.6M
What is the current EBITDA of Acumen Pharmaceuticals? Acumen Pharmaceuticals's last 12-month EBITDA is -$120M.
What is the current EV/EBITDA multiple of Acumen Pharmaceuticals? Current EBITDA multiple of Acumen Pharmaceuticals is 0.6x.
Is Acumen Pharmaceuticals profitable? Yes, Acumen Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.